Neutropenia (all grades CTC) occurred after 24 administrations (8.6%) and was grade ≥ 2 in 8 courses (2.9%), and grades 3 and 4 in 5 and 3 courses, respectively. Thrombocytopenia grade ≥ 2 occurred in 10 courses (3.6%), and was grade 3 in 3 cycles. No patient developed grade 4 thrombocytopenia.

No statically significant relationship was found between age and primary diagnoses.

Conclusion and relevance Although the incidence was low, severe and life threatening myelotoxicity was a serious side effect in non-cancer patients receiving cyclophosphamide and should be closely monitored.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. Katsifis GE, Tzioufas AG, Vlachoyiannopoulos PG, *et al.* Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. *Rheumatology (Oxford)* 2002;41:780–786.

No conflict of interest.

4CPS-083 SAFETY AND TOLERABILITY OF PALBOCICLIB IN CLINICAL PRACTICE IN A TERTIARY HOSPITAL

¹J Fernández Fradejas*, ¹L Quesada-Muñoz, ¹M Vélez-Díaz-Pallarés, ²E Vida Navas, ²A Cortés Salgado, ¹A Cabello Bravo, ¹T Bermejo Vicedo. ¹Hospital Universitario Ramón Y Cajal, Pharmacy, Madrid, Spain; ²Hospital Universitario Ramón Y Cajal, Oncology, Madrid, Spain

10.1136/ejhp-2020-eahpconf.184

Background and importance Due to its recent commercialisation, the safety profile of palbociclib is undergoing special surveillance. Tolerability and safety problems often lead to dose reductions, introduction of supportive treatment or even treatment discontinuation.

Aim and objectives To evaluate the safety and tolerability of palbociclib in clinical practice in a third level hospital.

Material and methods This was retrospective cohort study. Inclusion criteria were all patients who started treatment with palbociclib between 1 January 2019 and 31 August 2019. Toxicity level was classified according to CTCAE V5.0. Demographic and clinical data were collected from the patient electronic medical records.

Results Forty patients were included (n=40), all women, with a median age of 60 years (range 34–88). All had an ECOG performance status of 0–1 at the time of initiation of palbociclib. Ten patients received palbociclib in combination with fulvestrant and 30 in combination with an aromatase inhibitor. The median number of cycles received was 4 (1–8).

Haematological toxicities detected were grade 1–2 neutropenia (30% of patients), grade 3–4 neutropenia (47%), thrombocytopenia (37%), anaemia (45%), lymphopenia (7%) and leucopenia (35%). No patient suffered from febrile neutropenia. The incidence of infections during treatment was 5%. Other non-haematological adverse events detected with an incidence $>5\%$ included asthenia (15%), nausea (15%) and hypertransaminasaemia (7%).

Toxicity led to delay or temporary interruption of treatment in 50% of patients (median 1 interruptions/delays of treatment, range 1–3). Dose reduction to 100 mg was required in 22.5% of patients. No patient required a second reduction in dose. Three patients (7.5%) required administration of G-CSF as supportive therapy. Only one patient had to stop treatment permanently due to toxicity.

Conclusion and relevance Our population showed mainly haematological toxicities, with an incidence of neutropenia similar to clinical trials. However, the incidence of infections and non-haematological toxicities was generally lower than reported in clinical trials, probably due to the short revision period. Treatment was generally well tolerated in most patients, and adverse events were easily controlled, preventing patients from discontinuing treatment permanently. Further research will be needed to determine whether delays/temporary interruptions of treatment and dose reductions might affect its efficacy in the long term.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-084 ANTHRACYCLINE DOSAGE IN PAEDIATRIC OBESE PATIENTS

B Fernandez García*, C Fraile Rodríguez, X Abasolo Tamayo, I Herrero Corell, M Serrano Alonso, M Á García-Del-Barrio. *Clinica Universidad De Navarra, Pharmacy, Pamplona, Spain*

10.1136/ejhp-2020-eahpconf.185

Background and importance In 2016, the World Health Organization estimated that 41 million children aged <5 years were overweight. Clinicians are increasingly likely to have obese children requiring chemotherapy under their care. Optimal drug dosing for this population is unclear. Anthracyclines are often used in paediatric cancers and given its cardiotoxicity, optimising the dose is mandatory.

Aim and objectives To clarify the most adequate anthracycline dose in obese children with the available safety, effectiveness, pharmacokinetic and pharmacodynamic data.

Material and methods A systematic review was carried out in PubMed, Scopus and Web of Science in March 2019 with ‘obese OR obesity’ in the title and the name of each drug (daunorubicin/doxorubicin/epirubicin/idarubicin) in the topic or equivalent. Articles with a reference to the paediatric population in the title were included. Those that did not provide relevant information for the purpose of our study, written in a language other than English/Spanish and which did not allow conclusions to be made were excluded. Articles that used a different obesity criterion were selected when providing data of interest. Article references were reviewed to identify additional studies.

Results Fourteen articles were found. Ten were excluded because no dosage information was given or because of duplications. Four articles were analysed: three for doxorubicin and one for daunorubicin. The efficacy of doxorubicin was measured in one article in which the patient achieved complete remission using adjusted doses. No changes in the ECG were found during treatment or at 2 months or 2 years after treatment ended. No other specific toxicity was observed. The pharmacokinetics of doxorubicin are controversial. One article found no difference in clearance using adjusted weight versus actual weight; the other showed lower clearance in obese paediatric patients than in normal weight paediatric patients ($p<0.05$).

For daunorubicin and doxorubicin, pharmacokinetic in vitro models suggested that the presence of adipocytes markedly reduced the clearance of chemotherapy agents used as induction therapy in ALL.

Conclusion and relevance It seems that adjusted doses of anthracyclines in obese paediatric patients can be effective and safety but due to limited data, this recommendation must be taken with caution.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-085 IMPROVED ACCESS TO CHEMOTHERAPEUTIC TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA

¹EG Fernández López*, ²MM Viña Romero, ²J Merino Alonso, ²JA De Leon Gil, ²I Gonzalez Perera, ²JA Martin Conde. ¹Hospital Nuestra Señora De Candelaria, Hospital Pharmacy, Santa Cruz De Tenerife, Spain; ²Santa Cruz De Tenerife, Spain

10.1136/ejhp-pharm-2020-eahpconf.186

Background and importance A hospital complex has a reference centre that is a tertiary hospital to which is attached a regional hospital located 75 km away. In 2018, in coordination with the pharmacy and haematology service, it was decided to implement a monographic consultation for patient with multiple myeloma in the regional hospital, with the proposal to improve the accessibility of patients to chemotherapeutic treatments and avoid displacement to the centre of reference.

Aim and objectives To describe the activity carried out within the scope of a programme to improve accessibility for patients with multiple myeloma. User satisfaction with this new feature was evaluated.

Material and methods A retrospective descriptive study was conducted in April 2018 and September 2019. The following variables of the chemotherapy management programme (Farmis-Oncofarm) were recorded: number of patients treated, number of chemotherapy cycles administered and type of chemotherapeutic scheme. To evaluate patient satisfaction, we obtained 30 anonymous and voluntary evaluations in which total satisfaction was rated from 1 to 10 and also satisfaction per item.

Results A total of 46 patients were treated during the study period: 58% were men and average age was 62 years. A total of 382 cycles of parenteral chemotherapy and 145 cycles of oral chemotherapy were administered. The schemes used were: VTD (bortezomib-thalidomide-prednisone), VMP (bortezomib-melfalan-prednisone), bortezomib-dexamethasone, daratumumab-bortezomib-dexamethasone, maintenance lenalidomide and Rd (lenalidomide-dexamethasone). Overall satisfaction by patients was 9.4. The best rated items were accessibility to the centre, proximity between the different units (haematology consultation, pharmacy and oncology day hospital) and waiting time.

Conclusion and relevance The implemented programme has been highly valued by patients. Seeking strategies aimed at improving the accessibility of patients to hospital treatments should be a priority for the health system. In our case, the pathology required frequent and repeated cycles of chemotherapy in fragile and elderly patients. This added to the ease of administration (subcutaneous and oral routes) making multiple myeloma a candidate pathology to follow-up in a regional hospital without jeopardising patient safety.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-086 IMATINIB DOSE OPTIMISATION THROUGH THERAPEUTIC MONITORING IN CHRONIC MYELOID LEUKAEMIA AS PART OF PHARMACEUTICAL CARE

¹C Fernandez Oliveira*, ¹E Fernández Gabriel, ¹M Outeda Macías, ²MS Noya Pereira, ¹I Martín Herranz. ¹Complejo Hospitalario Universitario A Coruña, Pharmacy Service, A Coruña, Spain; ²Complejo Hospitalario Universitario A Coruña, Haematology Service, A Coruña, Spain

10.1136/ejhp-pharm-2020-eahpconf.187

Background and importance Chronic myeloid leukaemia was the first haematological neoplasia to benefit from imatinib targeted therapy. The standard dose of imatinib is 400 mg/day, although it is related to interpatient variability in plasma exposure. The relationship between treatment outcomes and plasma exposure has been established; predose plasma concentrations (C_{min}) ≥1000 ng/mL are associated with improved clinical response, which supports dose optimisation through therapeutic monitoring.

Aim and objectives Our aim was to describe the degree of implementation of C_{min} assessment based on response status and individual tolerance and to determine the impact of imatinib therapeutic monitoring in daily clinical practice in a tertiary hospital.

Material and methods This was an observational retrospective study in a university hospital. All patients being treated with imatinib between December 2016 and March/2019 were reviewed. Demographic and clinical data were collected (sex, diagnosis age, imatinib starting time, C_{min}, BCR-ABL ratio and information concerning medical and pharmaceutical care consultation). C_{min} was quantified by the nanoparticle agglutination immunoassay in human plasma.

Results Eighty-seven patients received active treatment (56% men). Age of diagnosis was 52±17 years and 74% (65/87) of patients were treated with imatinib. Treatment monitoring occurred in 66% (43/65) of patients. Time between treatment start time and C_{min} monitoring was 60.8 (2.5–509) months and 2 (1–7) samples were analysed per patient: 63% (27/43) of patients had C_{min} ≥1000 ng/mL since the first monitoring: 1156 (1033–2972) ng/mL (74% treated with 400 mg/day, 15% 300 mg/day, 7% 200 mg/day and 4% 600 mg/day). In 15% (4/27) of patients where appropriate C_{min} was reached from the beginning, the dosage was reduced, maintaining them within optimal concentrations. In 38% (16/43) of patients, C_{min} was <1000 ng/mL in the first monitored sample: 673 (444–999) ng/mL (75% treated with 400 mg/day and 25% 300 mg/day). In 88% (14/16) of patients with subtherapeutic C_{min}, a new C_{min} was studied: 939 (363–1352) ng/mL. In 43% (6/14) dose interventions were done (dose increased in 50% (3/6), 67% reached C_{min} ≥1000ng/mL). In 57% (8/14) of patients with subtherapeutic levels, the dose was not modified due to a good treatment response (680 (525–999) ng/mL).

Conclusion and relevance Most patients reached optimal imatinib plasma concentrations with a standard dose. The